Renata Szyszka, Ph.D. is in her mid-40s and is in charge of global coordination and strategic development for Advanced Translation for LCA therapies. She is interested in integrating basic research and foundational studies with clinical implementation and post-market approval.
The University of Gdansk in Poland awarded Dr. Szyszka an MS with honors in 2003, and Drexel University in the United States awarded her a Ph.D. in analytical chemistry (MALDI TOF-MS) in 2012. She specializes in developing exploratory technologies for the treatment of rare diseases and has extensive experience in the field of advancing translational sciences.
At the primary research and development facility for Arkema in King of Prussia, Pennsylvania, she began her career in 2003 as a research intern. Later, she relocated to Polpharma S.A, the current market leader in generic pharmaceuticals, where she gained experience as an analytical chemist. There, she worked until 2007. She subsequently made the decision to attend Drexel University in Philadelphia to finish her Ph.D., where she worked up until 2012. Since then, she has held leadership and scientific positions with both established corporations and start-ups, such as Cordis Corporation- A Johnson and Johnson Company (PA, USA), Pharmaceutical Research Institute (PL), ProQR Therapeutics B.V. (NL), and Pall Life Sciences (UK).
She worked arduously and devotedly to pave her way to success. She made a change and accepted the position of Chief Visionary Officer at E&ILCA, an enterprise she created and has been growing since 2016. Global Executive Leadership and a strong drive for research and innovation rank among her strongest qualities. She builds enterprises from the ground up. She successfully transforms enormous challenges into wonderful possibilities thanks to her entrepreneurial mindset. Personally humble and firmly planted on the earth.
The world is completely dark when I close my eyes. I can only hope that it is only temporary since I am unable to see everyone I care about. I can not appreciate the beauty of a setting rainbow, yellow sun, or brilliant stars on a summer night.
Your newborn baby, the love and life you invested in its little, ideal body, is beginning to lose its vision. In a few years, she or he will step into the realm of empty spaces. Like the majority of parents, you most likely don’t know someone who is blind. However, you do now. Infancy or early childhood sufferers of Leber’s congenital amaurosis (LCA), an inherited retinal disease, experience severe vision impairment. Lack of information causes a delay in the condition’s diagnosis. There is presently no treatment for it. – What’s next?
I really believe that we are capable of healing any illness and alleviating any kind of pain. I believe in offering complete treatment to those with uncommon diseases. What makes me an essential component of this vast ecosystem based on the study of life?
It is the original hypothesis that, if we can raise Key Opinion Leaders’ (KOLs’) knowledge of what it really means to be blind, the lengthy and expensive process of medication development could start to be enjoyable.
By introducing patients to KOLs, we raise engagement for everyone.
Should we provide more details about the importance of the essential needs, assistive technology, and white canes used by blind people?
– We’ll transform into innovative proponents of novelty. Should we emphasize how important guiding dogs are?
– We’ll keep in touch with our genuine emotional desires. Should we stress how important education and braille reading are?
– Visually healthy people provide themselves the chance to approach scientific problems differently and come up with fresh solutions. We allow for empathy while maintaining strong business & legal standards, making us exceptional innovators throughout the entire process of bringing breakthrough medicines to life.
PROFESSIONAL RECOGNITIONS & PERSONAL DEVELOPMENT
- Recommendations for genetic privacy policies together with some chosen cases for discussion. January 3, 2023.
- Introduction to Rare Diseases produced by Ågrenska September 17, 2021 (pdf).
- How the oligonucleotide and peptide industries are shifting – INDUSTRY VOICES, May 29, 2018.
- Rejected. Applied for a job and did not get accepted. Ouch!. June 7, 2017.
- ISPOR Asia Consortium Pharmaceuticals & Biologics Committee/ Health Technology Producers (Industry) Committee, March 6, 2017.